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Purpose.  – Management  of giant cell  arteritis  (GCA,  Horton’s  disease)  involves  many  uncertainties.  This
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eywords:
work  was  undertaken  to establish  French  recommendations  for  GCA  management.
Methods.  – Recommendations  were  developed  by  a multidisciplinary  panel  of  33 physicians,  members
of  the  French  Study  Group  for Large  Vessel  Vasculitis  (Groupe  d’étude  franc¸ ais  des  artérites  des  gros  vais-iant cell arteritis
ecommendations
iagnosis
reatment
seaux  [GEFA]).  The  topics  to be addressed,  selected  from  proposals  by group  members,  were  assigned
to  subgroups  to summarize  the available  literature  and  draft recommendations.  Following  an  iterative
consensus-seeking  process  that  yielded  consensus  recommendations,  the  degree  of agreement  among
panel  members  was  evaluated  with  a 5-point  Likert  scale.  A recommendation  was approved  when  ≥ 80%
of  the  voters  agreed  or strongly  agreed.
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Results.  –  The  15  retained  topics  resulted  in  31 consensus  recommendations  focusing  on  GCA nomencla-
ture  and  classiﬁcation,  the  role  of  temporal  artery  biopsy  and  medical  imaging  in  the  diagnosis,  indications
and  search  modalities  for involvement  of  the aorta  and its  branches,  the  glucocorticoid  regimen  to  pre-
scribe,  treatment  of  complicated  GCA, indications  for use  of  immunosuppressants  or targeted  biologic
therapies,  adjunctive  treatment  measures,  and  management  of  relapse  and  recurrence.
Conclusions.  –  The recommendations,  which  will  be updated  regularly,  are  intended  to guide  and  harmo-
nize  the  standards  of  GCA  management.
© 2016  Société  nationale  française  de  médecine  interne  (SNFMI).  Published  by Elsevier  Masson  SAS.
All rights  reserved.
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summary of the literature and to propose 1 or more outlinesGiant cell arteritis (GCA), also called Horton’s disease in French
erminology, is a vasculitis of large-sized vessels of unknown eti-
logy. This rare disease predominantly affects women, northern
uropeans and people over 50 years of age, with its incidence peak-
ng between 70 and 80 years. Clinically, GCA bears a risk of sudden
ision loss and increased intermediate and long-term cardiovascu-
ar morbidity and mortality [1–3]. GCA is diagnosed and treated in
ospitals and private practice [4].
Numerous uncertainties persist with regard to optimal GCA
anagement. GCA diagnosis based on temporal artery biopsy (TAB)
nd glucocorticoid-treatment regimens [2,3] are not completely
eﬁned. In addition, the advent of modern vascular imaging tech-
iques and the description of new therapeutic agents and strategies
ave led to diverse management protocols. The literature on these
ubjects is difﬁcult to interpret because of discordant ﬁndings and
he lack of robust studies.
These considerations prompted the French Study Group for
arge vessel vasculitis (Groupe d’étude franc¸ ais des artérites des gros
aisseaux [GEFA]) to devise recommendations for GCA manage-
ent. The objectives were to reach consensus among experts’
iverse practices and to propose guidelines for hospital physicians
nd less specialized private practitioners.
. Material and methods
.1. Study group
A panel of GEFA members developed the recommendations. The
EFA is mostly composed of teaching hospital physicians special-
zed in internal medicine who share an interest in managing and
onducting research on GCA. An initial panel of 14 experienced
senior” GEFA members volunteered to participate in this project.
fter the “initial panel” had selected the topics to be addressed,
t designated 7 “junior” physicians, all internists or trainees in
nternal medicine, whose speciﬁc task was to help with the liter-
ture search. In addition, a radiologist, a pathologist and a nuclear
edicine specialist with practical experience in GCA management
greed to join the “enlarged panel” to help on one or several top-
cs. Subsequently, the panel was completed by the addition of 9
ther senior GEFA members (8 internists, 1 rheumatologist) who
esponded positively to an invitation to take part in it. These addi-
ional participants were asked to give their independent opinions
n the literature synthesis and the proposed recommendations.
ll 33 physicians of the “ﬁnal panel” worked in university hos-
itals or tertiary care centers. Several panel members were also
ascular medicine specialists and 1 worked in an ophthalmologic
ospital.
A 5-member Steering and Writing Committee of senior panel
embers (BB, KHL, ML,  LS, AM)  was responsible for organizing and
anaging face-to-face meetings, e-mail correspondence, prepa-
ation and distribution of the iterative versions of the written
ocuments, electronic polling, searching the literature to identify
elevant publications during the development of the recommenda-
ions, and manuscript preparation.Fig. 1. Schematic diagram of the procedure used to obtain the consensual GCA
recommendations.
1.2. Development of recommendations
Fig. 1 outlines the main stages of the procedure followed to
develop recommendations. The 14 initial panel members agreed
on the topics via e-mail exchanges. The topics proposed by a
panel member were discussed and the ﬁnal selection was based
on the following criteria: 1) has an impact on clinical practice; 2)
has resulted in publications of original data; and 3) could beneﬁt
from standardized practices because of discordance among practi-
tioners. For each selected topic, a deﬁnition of the question and
the objectives of the recommendation were drafted. The topics
were assigned to subgroups of 2 or 3 senior physicians and 1
or 2 junior physicians; the topic distribution took into consider-
ation the preferences expressed by the senior members. Subgroups
were instructed to conduct a systematic literature review focus-
ing on articles published during the past 20 years, to write afor recommendations. Subgroups had 3 months to complete this
task.
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Table 1
Topics retained for the development of recommendations and objective of each recommendation.
No. Topic Statement of objectives
1 Terminology Decide on the name(s) to use to designate giant cell arteritis (GCA)
2  Nomenclature and classiﬁcation Decide on the deﬁnition and classiﬁcation system to adopt for GCA
3  Clinical diagnosis Decide under what circumstances a clinical diagnosis of GCA is acceptable or requires
conﬁrmation by additional diagnostic tests
4  Temporal artery biopsy (TAB) Determine the role of TAB (and how it should be obtained and processed) in the diagnostic
work-up for GCA
5  Temporal artery imaging Determine the roles of temporal artery imaging and the technique(s) to be used in the
diagnostic work-up for GCA compared to TAB
6  Imaging of the aorta and its branches to diagnose GCA Determine the roles of imaging of the aorta and its branches in the diagnostic work-up for
GCA  and the technique(s) to be used compared to TAB
7  Biomarkers Deﬁne which biomarkers are useful for GCA diagnosis and follow-up
8  Search for aortic complications Decide the rationale and imaging modalities to screen for complications of aortic
involvement in patients with established diagnoses of GCA
9  Glucocorticoid treatment of uncomplicated GCA (i.e.,
without ophthalmic involvement and without arteritis of
the aorta or its branches)
Deﬁne the glucocorticoid regimen for the treatment of uncomplicated GCA
10  Treatment of GCA with ophthalmic involvement Deﬁne the treatment of GCA (or suspected GCA) with ophthalmic involvement
11  Treatment of GCA with aortoarteritis Deﬁne the treatment of GCA with involvement of the aorta or its branches
12  Adjunctive immunosuppressant or immunomodulatory
therapy
Deﬁne the indications and regimens for the use of adjunctive immunosuppressive or
immunomodulatory agents to treat GCA
13  Targeted biologic therapies Deﬁne the role of targeted biologic therapies in the treatment of GCA
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15  Treatment of relapse and recurrence Deﬁne
The consensus-seeking process was based on a modiﬁed nom-
nal group technique [5] and consisted of 2 face-to-face meetings
eld 6 months apart. During the ﬁrst meeting, the subgroups
resented their syntheses of literature ﬁndings and 1 or more
roposals for recommendations for the topic(s) treated. This infor-
ation and the proposals were debated and the panel decided
hich recommendations could be proposed for each topic. After
hat meeting, a “synthesis document” was prepared, consisting
f a summary of the ﬁndings reported in the literature review
nd drafted recommendations for each topic, which was sent to
ll panel members before the second meeting. During the sec-
nd meeting, each proposed recommendation was thoroughly
iscussed, and the group decided the need for and types of modiﬁ-
ations required. After the second meeting, the recommendations
ere revised in accordance with the outcomes of those discus-
ions. Questions with consensus difﬁculties and that required
econsideration of literature observations were modiﬁed with the
greement of the subgroup responsible for the corresponding topic.
he new version of the synthesis document was then sent via
-mail to all panel members for their additional comments. Lin-
ering disagreements were openly addressed and discussed in
-mails.
The recommendations were then subjected to a vote of approval
ia a poll conducted with the online tool SurveyMonkey®. Each
tem of a recommendation was evaluated on a 5-point Likert
cale, ranging from “Strongly agree” to “Strongly disagree” and
ith a “Neutral” response at the midpoint. All members of the
nal panel had to vote, except for the 3 not involved in clinical
are who could opt for a “No opinion” response. A minimal con-
ensus threshold of 80% of the responses being “Strongly agree”
r “Agree” was established to accept that consensus had been
ound; the “No opinion” responses were not counted in the denom-
nator of the computations. The items for which the threshold
as not reached or for which other questions were raised were
ubjected to a new vote after being rephrased. The agreement
evel of each recommendation was also expressed as a median
interquartile range [IQR]) calculated by weighting each response
evel by values ranging from 5 (for “Strongly agree”) to 1 (for
Strongly disagree”). Higher medians indicated higher agreement
evels and narrow IQR indicated higher consistency in the raters’
udgments.sefulness of low-dose aspirin or other adjuvant therapies during GCA and deﬁne
ions and prescription regimens
eatment of GCA relapse or recurrence
1.3. Publication procedure
All the work documents, including the synthesis document with
the literature review summaries and recommendations, were writ-
ten in French. The ﬁnal version of the synthesis document was
included in its entirety in the manuscript. After being approved
by all the authors, the complete manuscript was translated by
an experienced, native English-speaking biomedical translator and
submitted for publication in English. After acceptance for publica-
tion of the English version, the modiﬁcations made in response to
peer review comments were included in the French text for simul-
taneous publication of both versions.
2. Results
The development of recommendations lasted from February
2014 to May  2015. The topics selected and their respective objec-
tives, given in Table 1, covered terminology (1 topic), nomenclature
and classiﬁcation (1 topic), diagnostic methods (6 topics) and treat-
ment guidelines (7 topics). The literature summaries for each topic
treated are given in the following sections, followed by a short com-
mentary highlighting the panel’s opinion on the interpretation of
available information.
The panel’s consensus recommendations are reported in Table 2.
The 15 topics addressed resulted in 31 recommendations. All the
recommendations reached 80% agreement and weighted agree-
ment medians of 4 or 5 (Table 2, Fig. 2). The agreement level also
reached 80% when the calculations were based on the responses
for only the 26 senior panel members (data not shown).
2.1. Topic 1: terminology
GCA has been given several names. “Temporal arteritis” or “cra-
nial arteritis” were extensively used to designate GCA but have
fallen into disuse. “Horton’s disease” is mainly used in Europe, espe-
cially in France, after the American neurologist who contributed
to its description in 1932 [6]. GCA is the most-used term today,
in almost 70% of the publications [7] and was adopted by the
International Chapel Hill Consensus Conference Nomenclature of
Vasculitides [8,9] and American College of Rheumatology (ACR)
[10] classiﬁcation of vasculitis.
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Table 2
Recommendations retained for 15 topics concerning giant cell arteritis (GCA) management.
Item Recommendation Level of agreementa
Strongly agree or agree (%) Median (IQR)
Topic 1: terminology
1a The term “giant cell arteritis” (GCA) or “giant cell arteritis (Horton’s)” should be used 100 5 (0)
Topic  2: nomenclature and classiﬁcation
2a GCA should be deﬁned as arteritis of the aorta and/or its branches in a person > 50 years
of  age with cranial (clinical or histological) or ophthalmic involvement
93.8 5 (1)
2b  For research purposes, the American College of Rheumatology (ACR) classiﬁcation criteria
should be used to classify a vasculitis as GCA
96.9 5 (1)
Topic  3: clinical diagnosis
3a GCA diagnosis should be considered particularly in patients > 50 years of age with
new-onset headaches, jaw claudication, abnormal temporal artery on physical
examination or visual symptoms of sudden onset
100 5 (0)
3b  We do not advise determining a diagnosis of GCA with high certainty based on clinical
ﬁndings alone and without performing additional diagnostic tests
96.8 5 (0.5)
Topic  4: temporal artery biopsy (TAB)
4a TAB should be obtained to determine the diagnosis of GCA with high certainty, but it
should not delay treatment initiation, and a negative biopsy does not exclude the diagnosis
100 5 (0)
4b  TAB ﬁndings are compatible with GCA in the presence of mononuclear cell inﬁltrates of
the  media; additional ﬁndings of giant cells in the inﬁltrate and/or elastophagia can be
considered highly speciﬁc for GCA
100 5 (1)
4c  First-line TAB strategy should be based on a unilateral biopsy, at least 1-cm long and
examined in numerous serial sections
100 5 (0)
Topic  5: temporal artery imaging
5a Temporal artery imaging with Doppler ultrasonography or MRI  cannot replace the TAB as
the  ﬁrst-choice diagnostic examination
93.8 5 (1)
5b  Doppler ultrasonography of the temporal arteries must be performed by an experienced
operator
100 5 (0)
5c  MRI of the temporal arteries is not recommended 93.9 4 (1)
Topic  6: imaging of the aorta and its branches to diagnose GCA
6a  A clinical diagnosis of GCA can be supported by angio-CT, angio-MRI or 18FDG-PET-scan
demonstration of arteritis of the aorta or its branches, but imaging of the aorta and its
branches cannot replace the TAB as the ﬁrst-choice examination
93.9 5 (0)
Topic  7: biomarkers
7a Laboratory tests in the diagnostic work-up of GCA should include measurements of
C-reactive protein and an inﬂammatory marker with slower response (erythrocyte
sedimentation rate or ﬁbrinogen)
100 5 (1)
7b  We do not recommend measuring biomarkers other than C-reactive protein, erythrocyte
sedimentation rate and ﬁbrinogen in the diagnostic work-up of GCA or for monitoring
disease activity
96.8 5 (1)
Topic  8: search for aortic complications
8a CT or MRI  screening for complications of aortitis is recommended at GCA  diagnosis, then
every 2–5 years, provided the patient has no contraindications to a potential aorta repair
93.8 5 (1)
Topic  9: glucocorticoid therapy of uncomplicated GCA (i.e., without ophthalmic involvement and without arteritis of the aorta or its branches)
9a  We recommend treating uncomplicated GCA with oral prednisone at a starting dose of
0.7  mg/kg/day, then gradually tapering to reach 15–20 mg/day at 3 months,
7.5–10 mg/day at 6 months, 5 mg/day at 12 months and weaning off glucocorticoids
within 18–24 months
100 5 (1)
9b  The systematic initiation of treatment with intravenous methylprednisolone pulse(s) is
not recommended
100 5 (0)
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Table 2 (Continued )
Item Recommendation Level of agreementa
Strongly agree or agree (%) Median (IQR)
Topic 10: treatment of GCA with ophthalmic involvement
10a Suspected GCA with transient or permanent ophthalmic involvement should be treated
immediately with 1 mg/kg/day of oral prednisone or 500–1000 mg/day of intravenous
methylprednisolone for 1–3 days (followed by oral prednisone at 1 mg/kg/day), according
to  the regimen that can be most rapidly initiated
100 5 (0)
10b  The tapering schedule and duration of glucocorticoid treatment for GCA with ophthalmic
involvement should follow the same regimen as that recommended for uncomplicated
GCA
96.8 5 (1)
10c  Aspirin (75–300 mg/day) should be advised for GCA with ophthalmic involvement 96.8 5 (1)
Topic  11: treatment of GCA with aortoarteritis
11a GCA with uncomplicated and asymptomatic involvement of the aorta or its branches can
be  treated with the glucocorticoid regimen recommended for uncomplicated GCA
90.3 5 (1)
11b  For complicated (dilation, aortic aneurysm or dissection) or symptomatic (limb
claudication or ischemia) aortoarteritis at GCA onset, oral prednisone at 1 mg/kg/day can
be  prescribed as a starting dose
87.1 4 (1)
11c  Except for emergency situations, repair of an aortic lesion should be scheduled once the
systemic inﬂammatory response has subsided
93.8 5 (0)
Topic  12: adjunctive immunosuppressant or immunomodulatory treatment
12a The systematic prescription of an immunosuppressant or immunomodulatory agent for
newly-diagnosed GCA is not recommended
100 5 (0)
12b  Adjunctive immunosuppression with methotrexate could be considered in selected
patients with newly-diagnosed GCA for whom glucocorticoid-sparing is a major concern
87.1 4 (1)
Topic  13: targeted biologic therapies
13a Prescribing a targeted biologic therapy at GCA diagnosis is not recommended 93.5 5 (0)
Topic  14: aspirin, anticoagulants and statins
14a Low-dose aspirin (75–300 mg/day) should be considered for every patient with
newly-diagnosed GCA upon beneﬁt–risk assessment; for GCA with ophthalmic
involvement, prescribing low-dose aspirin should be advised
100 5 (1)
14b  The systematic prescription of an anticoagulant or a statin is not recommended 93.5 4 (1)
Topic  15: treatment of relapse and recurrence
15a For a ﬁrst relapse or recurrence, treatment with glucocorticoids is recommended at a dose
that  depends on symptom severity and by at least returning to the previously effective
dose
100 5 (0)
15b  For multiple relapses or recurrences or patients with glucocorticoid-dependent GCA on
10–15 mg/day of prednisone (or an equivalent compound), adjunctive methotrexate can
be  prescribed; tocilizumab can be considered in case of methotrexate failure
93.5 4 (1)
15c  A purely biological “relapse” or “recurrence” does not necessarily require glucocorticoid
dose intensiﬁcation or the initiation of adjunctive therapy but should prompt closer
monitoring
96.8 5 (1)
18FDG-PET: 18ﬂuorodeoxyglucose positron-emission tomography; MRI: magnetic resonance imaging; CT: computed tomography.
a The level of agreement for each of the 31 recommendation items corresponds to the percentage of panel voters who  indicated “Strongly agree” or “Agree” and the median (interquartile range [IQR]) calculated after weighting
the  evaluations by the voters among the Likert scale choices from 5 (“Strongly agree”) to 1 (“Strongly disagree”).
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Fig. 2. Distribution of the levels of agreement among the 33 panel members for
each of the 31 items (derived from the 15 topics) for which recommendations were
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pormulated. The item numbers and their corresponding recommendations are fully
eveloped in Table 2.
Comments: the term GCA is not limited to a histological ﬁnding
ut is a synonym of the anatomical-clinical entity “Horton’s dis-
ase”, including when TAB is negative for typical features of GCA.
n the French literature, the term “giant cell arteritis (Horton)” can
e used.
.2. Topic 2: Nomenclature and classiﬁcation
GCA is classiﬁed in the group of large-sized vessel vasculi-
ides and deﬁned as a disease affecting the aorta and its primary
ranches, with a predilection for external carotid and vertebral
rteries [9]. Takayasu disease, sometimes considered to form a syn-
romic spectrum with GCA [11], is distinguished from GCA mainly
y its onset before 50 years of age [9]. Polymyalgia rheumatica
nd isolated idiopathic aortitides can be differentiated from GCA
y their absence of cranial (clinical or histological) and ophthalmic
ymptoms and signs. Demographic and clinical characteristics of
solated idiopathic aortitis in older adults differ from those of GCA
12], and the most recent International Chapel Hill Consensus Con-
erence nomenclature considers it an entity distinct from GCA
9]. The ACR classiﬁcation criteria for GCA require cranial mani-
estations (recent onset headaches, abnormal temporal artery on
hysical examination or positive TAB result). They enable GCA to be
istinguished from another systemic vasculitis with 94% sensitivity
nd 91% speciﬁcity [10].
Comments: in the absence of documented vasculitis, classiﬁca-
ion of a disease as GCA is problematic. It can only be considered
y including other information, such as the response to glucocorti-
oids and evaluation of the disease course during patient follow-up.
.3. Topic 3: clinical diagnosis
Some clinical signs are highly suggestive of a diagnosis of GCA.
he results of a large meta-analysis [13] suggested that claudi-
ation of the jaw (34% of the patients) and diplopia (9%) are the
 clinical manifestations most strongly predictive of TAB-positive
CA (positive likelihood ratios: 4.2 and 3.4, respectively). Another
tudy showed that headaches (86%), claudication of the jaw (42%)
nd temporal artery abnormalities on physical examination (44%)
igniﬁcantly increased the probability of TAB-positive GCA (rela-
ive risk: 3.6, 2.9 and 2.5, respectively) [14]. In the presence of
olymyalgia rheumatica, the association of recent onset headaches,ine interne 37 (2016) 154–165 159
claudication of the jaw and a clinical temporal artery anomaly con-
fer a positive predictive value of 97% and positive likelihood ratio of
47 to support a diagnosis of GCA; disease onset after 70 years of age
increased the positive predictive value to 100%, but this association
was seen in only 27% of the patients with polymyalgia rheumatica
[15].
Comments: although not supported by study results, tongue
[16] or scalp necrosis [17] and acute ischemic visual disorders are
probably also strongly suggestive of GCA.
2.4. Topic 4: temporal artery biopsy
A diagnosis of GCA can be conﬁrmed by a TAB. The association
of an inﬂammatory inﬁltrate in the media with the presence of
giant cells and elastophagia can be considered characteristic of GCA
[18], but both of the latter features are not always found [19]. An
isolated, inﬂammatory periadventitial inﬁltrate [20,21] or vasculi-
tis (rarely necrotizing) of small vessels surrounding the temporal
artery [21–23] is less common and can also indicate a temporal
artery involvement of another systemic vasculitis [21,22,24].
The TAB is positive in 49%–85% of GCA patients [14,25–28].
These variations probably reﬂect differences in the clinical and
histological deﬁnitions of GCA as well as technical differences in
obtaining and processing the biopsy. The diagnostic yield seems
maximal for biopsies of at least 0.5–1 cm [29–32] and increases
somewhat with the multiplication of histological sections [20].
Compared to bilateral biopsies, a unilateral biopsy can identify 88%
of the TAB-positive GCA cases [33]. The contribution of Doppler
ultrasonography (US) to guide the site of TAB remains controver-
sial [34–36]. Histological anomalies are detectable for at least 15
days after glucocorticoids are started [37,38]. TAB complications
are rare [39].
Comments: no real consensus exists on the histological criteria
deﬁning GCA.
2.5. Topic 5: temporal artery imaging
Temporal artery imaging has been suggested as a valuable
modality for conﬁrming GCA. Color Doppler ultrasound (US) with
high-resolution linear probes is the most studied technique. A
hypoechogenic halo of the vessel wall [40] has 68% sensitivity (for
GCA meeting ACR classiﬁcation criteria) and 91% speciﬁcity [41].
Speciﬁcity increases when the halo sign is bilateral [41]. Sensitiv-
ity increases when halo signs of the axillary and common carotid
arteries are also considered [42].
Magnetic resonance imaging (MRI), 1.5 Tesla (1.5 T) or 3 T, with
gadolinium injection has been less studied. Vessel wall thickening
with contrast medium uptake and lumen reduction are suggestive
of the diagnosis [43]. The largest study, which considered tempo-
ral and occipital artery involvement, achieved 78% sensitivity and
90% speciﬁcity [44]. No signiﬁcant difference in diagnostic yield has
been found between Doppler US and 1.5 T or 3 T MRI  [45]; 1 T MRI
is not sufﬁciently sensitive [46].
Comments: imaging of the temporal artery does not support the
GCA diagnosis with as much certainty as TAB. The practical value of
Doppler US is difﬁcult to assess because of the heterogeneous study
ﬁndings and the high dependence on the operator for image acqui-
sition. In France, Doppler US is little used and has yielded mixed
results [47]. MRI, 1.5 T or 3 T, is even less well evaluated, is more
expensive and less available than Doppler US.
2.6. Topic 6: imaging of the aorta and its branches to diagnose
GCA
The detection of aortitis or arteritis of a branch of the aorta
can lead to suspicion of GCA and contribute to its diagnosis.
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he frequency of aortitis at GCA diagnosis has been most
xtensively evaluated by angio-computed tomography (CT)
cans [48–52], angio-MRI [53–56], 18ﬂuorodeoxyglucose
ositron-emission tomography (18FDG-PET) or 18FDG-PET scan
49,53–55,57–59]. Aortitis is usually deﬁned as regular circum-
erential wall thickening ≥ 2 or 3 mm on angio-CT images, wall
adolinium uptake on angio-MRI and homogeneous wall hyper-
etabolism on 18FDG-PET images. Its frequency on angio-CT or
ngio-MRI ranges from 33% to 65% [48–55]. According to 2 meta-
nalyses, the sensitivity and speciﬁcity of PET demonstration of
ortoarteritis at GCA diagnosis were 80% and 89% [60] and 90% and
8% [61], respectively. The results of a prospective study showed
hat the sensitivity of PET for detecting aortoarteritis was barely
uperior to that of MRI  [53]. The authors of a recent retrospective
tudy reported a greater ability of PET to detect inﬂammation of
orta branches than angio-CT [49]. Arterial Doppler US can reveal
alo signs of the common carotid [42], axillary and iliac-femoral
rteries [62,63].
Comments: literature ﬁndings are heterogeneous but indicated
hat imaging demonstration of aortoarteritis is less speciﬁc than
AB for GCA. Interpretation of imaging results remains difﬁcult
or aortic walls that are only moderately thickened, enhanced by
ontrast medium or hypermetabolic. Although PET could be more
ensitive for visualizing aortoarteritis, the choice among angio-CT,
ngio-MRI and PET should be made case by case and by taking
ccessibility into account.
.7. Topic 7: biomarkers
An erythrocyte sedimentation rate (ESR, Westergren) ≥ 50
m/h  is one of the ACR criteria for GCA classiﬁcation [64]. Inﬂam-
atory marker levels are almost always increased during the initial
hase of GCA, with a mean ESR of 93 mm/h  and a mean C-reactive
rotein (CRP) level of 94 mg/L [65]. Levels of other inﬂammatory
roteins (ﬁbrinogen, haptoglobin, orosomucoid) may  also be ele-
ated. Anemia of inﬂammation is seen in 55% of patients, and 49%
ave thrombocytosis [65]. Nonetheless, 11% of the patients have
SR < 50 mm/h  [66], and normal levels of inﬂammatory markers do
ot preclude a diagnosis of GCA [67]. An association between mod-
rately increased inﬂammatory marker levels and ocular ischemic
omplications has been reported [68].
Anti-cardiolipin [69–73], anti-endothelial cell [74,75] or anti-
uman ferritin heavy chain antibodies [76,77] have been detected
uring the course of GCA. Serum pentraxin-3 level is also elevated
n GCA [78]. A contribution to GCA diagnosis has not been demon-
trated for these biomarkers.
Comments: at present, there are no known speciﬁc biomark-
rs for the diagnosis of GCA or for determining distinct disease
henotypes or prognoses.
.8. Topic 8: search for aortic complications
The aortic aneurysm rate is higher for GCA patients than the
eneral population [79,80], especially in the ascending thoracic
orta (relative risk 17) [79]. According to cohort studies, the aortic
neurysm and/or dissection incidence was 19/1000 person-years
81,82]. An aneurysm can be discovered several years after GCA
iagnosis by an aortic dissection or rupture [79], but in 15% of
atients with aortitis, a thoracic aorta aneurysm or dilatation is
resent at GCA diagnosis [52]. Aortic aneurysm or dissection fol-
owing the diagnosis of GCA are associated with shortened survival
83].Comments: there are no known factors that can predict an aortic
omplication. The screening modalities (type of imaging, periodic-
ty) for aortic complications are not well deﬁned. For CT and MRI,
ontrast media is not required for analysis of the caliber of the aortaine interne 37 (2016) 154–165
but does enable evaluation of the vessel wall and lumen. Conven-
tional chest radiography has mediocre sensitivity to detect an aortic
abnormality [84].
2.9. Topic 9: glucocorticoids to treat uncomplicated GCA (i.e.,
without ophthalmic involvement and without arteritis of the
aorta or its branches)
Glucocorticoids are the historical gold standard for treatment
of GCA. The initial dose for uncomplicated GCA ranges from 0.3
mg/kg/day [85,86] to 1 mg/kg/day of prednisone or another equiv-
alent compound [87]. The results of some studies indicate that
0.5–0.7 mg/kg/day is usually adequate to control the disease and
is well tolerated [85,86,88,89]. A randomized clinical trial showed
that 3 consecutive daily intravenous methylprednisolone pulses
(15 mg/kg/day) before oral glucocorticoids was  beneﬁcial in reduc-
ing relapse rates and had an oral glucocorticoid sparing effect [90].
Prednisone has less inter-individual variability of plasma concen-
trations than prednisolone [91].
The initial dose is maintained for 2–4 weeks, depending on
how quickly the inﬂammatory syndrome subsides [92,93]. Glu-
cocorticoid tapering starts quickly to reach 0.2–0.3 mg/kg (15–20
mg/day) in 6–10 weeks [94]. Prospective and retrospective stud-
ies have shown that about half of patients achieve a dose of 0.13
mg/kg (7.5–10 mg/day) by 6 months [89,93]. Conversely, with-
drawal of steroids at 6 months of treatment in patients enrolled in
a controlled clinical trial resulted in a 77% relapse rate at 1 year of
follow-up [92]. Median treatment duration lasted about 24 months
in observational cohort studies with a wide range, often many years
[88,95].
Comments: no international consensus has been reached for the
initial glucocorticoid dose for uncomplicated GCA. The administra-
tion of methylprednisolone pulses to older patients or those with
comorbidities can be problematic.
2.10. Topic 10: treatment of GCA with ophthalmic involvement
Ophthalmic involvement is the most common severe GCA
complication, with 13%–19% of patients experiencing irreversible
ischemic injuries due to occlusion of ophthalmic artery branches
[25,96–99] or, more rarely, posterior occipital artery strokes
[96,100]. Visual acuity of the affected eye is < 20/200 for most
patients [101,102] and ophthalmic involvement occurs in both
eyes in one third. In 95% of the patients, visual impairment occurs
before starting glucocorticoids [96,99,103], with a mean interval
of 6 weeks after the ﬁrst symptoms [96,103,104]. In about 20%
of patients, ophthalmic involvement is the initial manifestation
[96,101,102]. A few patients starting glucocorticoids within 72
hours may  achieve partial visual improvement [105–107]. Ipsilat-
eral deterioration or contralateral amaurosis occurs in about 10%
of patients during the ﬁrst days of therapy [96,102,108].
The best therapeutic results were obtained with oral prednisone
(or its equivalent) of at least 60 mg/day [96,106,107,109] or 500 mg
of intravenous methylprednisolone [105–107,109]. The ﬁndings of
2 retrospective studies suggested that low-dose aspirin prevented
ocular and cerebral ischemic complications [98,110]. The potential
role of anticoagulants has not been adequately investigated [111].
Comments: we lack prospective study or controlled clinical trial
results to guide glucocorticoid regimens or use of low-dose aspirin
for GCA with ophthalmic involvement.
2.11. Topic 11: treatment of GCA with aortoarteritisArteritis of the aorta or its branches can be complicated by dila-
tion, aneurysm or dissection of the aorta and stenosis or occlusion of
a large branch of the aorta. Such complications raise the question of
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peciﬁc therapeutic measures, but no retrospective or prospective
tudy has compared different glucocorticoid regimens or evaluated
lucocorticoid-sparing treatments for GCA with aortoarteritis. Aor-
itis [112] or involvement of subclavian arteries [113], regardless of
he severity, could be associated with increased risk of relapse, glu-
ocorticoid dependency and cardiovascular mortality [112,113] but
emains controversial [114]. Aortic aneurysm or dissection (but not
tenosis of a large branch of the aorta) is associated with increased
ardiovascular mortality [83]. Prednisone (or an equivalent com-
ound) at 1 mg/kg/day is prescribed empirically for GCA with signs
f limb ischemia [115]. Endovascular treatment or surgery for an
ortic aneurysm follow the same treatment principles as those
pplied for situations not linked to GCA. Acute aortic dissection
s a surgical emergency.
Comments: whether GCA with uncomplicated and asymp-
omatic aortoarteritis requires more intensive medical therapy
emains an open question.
.12. Topic 12: adjunctive immunosuppressant or
mmunomodulatory therapy
The addition of immunosuppressive or immunomodulatory
gents to the therapeutic regimen to achieve glucocorticoid-
paring or to prevent relapse in GCA patients has been investigated.
djunctive methotrexate was examined in 3 randomized placebo-
ontrolled clinical trials [87,92,116], a meta-analysis of individual
atient data [117] and another meta-analysis of aggregated data
118]. According to the meta-analysis of individual data, oral
ethotrexate at 7.5–15 mg/week at diagnosis lowered the risk of
elapse and the cumulative glucocorticoid dose [117].
Other immunosuppressants or immunomodulators were eval-
ated during GCA, with negative or less robust results. Adjunctive
zathioprine (150 mg/day) was assessed in an early random-
zed placebo-controlled trial conducted on a small sample of
atients with GCA or polymyalgia rheumatica. The results showed
 glucocorticoid-sparing effect of azathioprine at month 12 of
ollow-up [119]. Randomized clinical trials of adjunctive therapy
ith cyclosporine [120], hydroxychloroquine [121] or dapsone
122] found either no efﬁcacy [120,121] or tolerance problems
121,122]. Uncontrolled retrospective studies reported the beneﬁ-
ial effects of cyclophosphamide [123–125], leﬂunomide [126,127]
r mycophenolate mofetil [128] on control of GCA.
Comments: at present, we have insufﬁcient evidence to
dvocate the use of an adjunctive immunosuppressive or
mmunomodulatory agent other than methotrexate. The efﬁcacy
f methotrexate seems modest.
.13. Topic 13: targeted biologic therapies
The advent of targeted biologic therapies raised the question
f their potential beneﬁt in GCA treatment to prevent relapse or
educe glucocorticoid exposure. Data from prospective studies on
he use of biologic drugs at GCA diagnosis as glucocorticoid-sparing
gents are available for only anti-tumor necrosis factor-alpha (TNF-
). Three randomized trials evaluating inﬂiximab, etanercept or
dalimumab did not show any beneﬁt for the primary endpoints
93,129,130]; the smallest of those trials found an etanercept effect
n a secondary endpoint with a statistically signiﬁcant reduction
f cumulative glucocorticoid doses after 12 months of treatment
130].
The only available information for other biologic therapies
s from uncontrolled studies examining patients with relaps-
ng or refractory GCA, generally after the use of methotrexate.
ocilizumab is currently the most promising biologic therapy.
t markedly reduces inﬂammatory biomarkers and appears very
ncouraging for clinical and imaging outcome measures [131–142].ine interne 37 (2016) 154–165 161
The efﬁcacy of anakinra or rituximab was  reported for 3 [143] and
2 patients with GCA [144,145], respectively.
Comments: the side effects of tocilizumab (notably infectious,
hematological, hepatic and gastrointestinal) and the current lack of
robust evidence of efﬁcacy should prompt caution while awaiting
the results of an ongoing international randomized placebo-
controlled clinical trial of this agent for management of GCA [146].
2.14. Topic 14: aspirin, anticoagulants and statins
For GCA patients, the increased short-term risk of ocular, cere-
bral and cardiovascular ischemic events [99,147] and increased
intermediate- and long-term risk of cardiovascular and cerebral
ischemic events [100,147–149] raise the question of measures con-
ferring vascular protection. For GCA patients taking glucocorticoids,
the results of several cohort and retrospective studies [98,110,150]
and a meta-analysis of retrospective studies [151] suggested that
low-dose aspirin (≤ 100 mg/day), given for primary [98] or sec-
ondary prophylaxis [151], diminished the risk of cerebral or ocular
ischemic attacks and the risk of cardiovascular events in gen-
eral. Another retrospective study indicated the protective effect
of low-dose aspirin on risk of relapse [152]. The possible ben-
eﬁt of anticoagulants is poorly documented [110]. The effect of
statins on the risk of cardiovascular complications during GCA has
not been evaluated. The ﬁndings of 3 retrospective cohort studies
[153–155] showed no advantage of statin use in terms of glucocor-
ticoid sparing effect, whereas an observational population-based
study suggested a beneﬁt of statins on reducing the duration of
glucocorticoid use [156].
Comments: as a matter of principle, prophylactic low-dose
aspirin or statin use should follow the current recommendations
for preventing complications of atherosclerosis.
2.15. Topic 15: treatment of relapse and recurrence
At least one third of patients experience clinical–biological
relapse or recurrence of GCA previously in treatment-induced
remission [157,158]. Some authors distinguish between relapse
that appears under treatment and recurrence that occurs at some
time after stopping glucocorticoids. The isolated reappearance of
increased inﬂammatory marker levels is usually not sufﬁcient to
diagnose a relapse.
No controlled trial has been conducted to guide the treatment
choices for GCA relapse or recurrence. The results of a meta-
analysis of data from patients with newly-diagnosed GCA who
participated in 3 randomized placebo-controlled clinical trials
indicated that methotrexate signiﬁcantly lowered the risk of 2
consecutive relapses [117]. The usefulness of cyclophosphamide
[123–125], leﬂunomide [126,127], mycophenolate mofetil [128]
or tocilizumab [131–141] to treat high-dose glucocorticoid-
dependent GCA or GCA with multiple relapses was  suggested by
uncontrolled studies usually involving small patient samples.
Comments: the management of GCA relapse and recurrence is
poorly deﬁned, and whether adjunctive therapy should be initiated
in such situations remains debated.
3. Discussion
The recommendations elaborated herein addressed 15 topics,
mostly referring to diagnostic and therapeutic aspects, for which
we perceived a need for harmonizing the standards of GCA manage-
ment. Although the panel was essentially composed of university
hospital physicians, these recommendations are also intended for
management of patients with GCA seen in non-teaching hospi-
tals and private practice. Except for possible differences across
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ations in healthcare systems or access to medications, these rec-
mmendations should also be applicable in countries outside of
rance.
Our recommendations should be viewed as the result of group
onsensus, deﬁned as approval by at least 80% of the voters and
hey do not necessarily reach unanimity among people outside our
anel. The results of original studies are prone to divergent inter-
retations, and several of our choices relied on clinical experience
riteria. The fact that most of the panel members were internists
aises the question of the generalizability of these recommenda-
ions to patients seen by other medical specialists. However, in
rance, internal medicine is a primary-care specialty which cares
or patients suspected of having GCA, and we believe that our
anel of 33 participants could offer comprehensive expertise on
he various situations practitioners may  encounter when caring for
atients with GCA.
We  decided not to score the level of evidence or grade our rec-
mmendations as “strong” or “weak” [159]. For a rare disease, the
carcity of original high-quality studies and the small number of
atients included in them means that the quality of evidence is
imited and thus provide little basis for this type of ranked evalua-
ion. Moreover, such notations are poorly applicable to older drugs,
uch as glucocorticoids, for which no proof of efﬁcacy was ever
rovided by a randomized clinical trial, or to the evaluation of diag-
ostic tests [160]. By contrast, we have highlighted the reasoning
hat has led to our recommendations in the commentaries accom-
anying the literature syntheses, and we reﬂected uncertainties
bout given recommendations in the prudent phrasing we have
hosen. Our degree of conﬁdence in each of the recommendations
s reﬂected by the levels of agreement, usually elevated, obtained
uring the validation process.
The topics dealing with the diagnosis and treatment of GCA
nvolving the aorta and its branches stirred ﬁerce discussions in
he process of reaching consensus. That debate reﬂects our current
nsufﬁcient knowledge of the best modalities to assess for involve-
ent of the aorta or its branches and the prognostic and therapeutic
mplications of such manifestations. We  also debated whether peo-
le > 50 years old diagnosed with isolated idiopathic aortitides
hould be considered as having GCA. The agreement adopted by our
roup stipulates that cranial or ophthalmic manifestations must
e present for a GCA diagnosis. As a consequence, these thera-
eutic recommendations are not implicitly applicable to isolated
diopathic aortitides. A better understanding of the relationships
etween GCA and the other idiopathic aortitis forms and of GCA
ubsets with distinct prognostic proﬁles represents a major future
esearch need.
The results of this work are only partially comparable to rec-
mmendations published under the aegis of the British Society
f Rheumatology (BSR) [161] or the European League Against
heumatism (EULAR) [162]. Our position on TAB as a ﬁrst-choice
iagnostic tool, as opposed to temporal or large-vessel imaging, is
n agreement with BSR and EULAR recommendations. In contrast,
ur recommendation concerning the indications for prescribing
djunctive immunosuppressant therapy, especially methotrexate,
s more conservative than that from the EULAR, which advises
rst-line methotrexate to treat GCA. A signiﬁcant contribution of
ur effort is that it devised recommendations for difﬁcult practical
uestions, such as treating GCA with aortoarteritis or the role of
argeted biologic agents to treat relapses.
In conclusion, these recommendations provide many practi-
al suggestions for GCA management. They will be expanded and
equire updating as new data become available, which will lead to
hanging the way we deﬁne, classify, diagnose and treat GCA. In
he future, the medical–economic characteristics of different diag-
ostic or therapeutic strategies, not addressed here because of our
ack of information, will also need to be considered.ine interne 37 (2016) 154–165
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